Treatment of retinopathy of prematurity: A review of conventional and promising new therapeutic options

International Journal of Ophthalmology

Volumn 6, Issue 2, 2013, Pages 228-236

  Mutlu, Fatih Mehmet ^a   Sarici, Serdar Umit ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Laser; Propranolol; Retina; Retinopathy of prematurity; Vascular endothelial growth factor

Indexed keywords

EID: 84885373571     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2013.02.23     Document Type: Review

References (110)

1. Palmer EA, Flynn JT, Hardy R.J., Phelps DL, Phillips CL, Schaffer DB, Tung B. Incidence and early course of retinopathy of prematurity: The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology. 1991; 98(11): 1628-1640.
2. Chow LC, Wright KW, Sola A, CSMC Oxygen Administration Study Group Can changes in clinical practice decrease the incidence of severe retinopathy of prematurity in very low birth weight infants? Pediatrics. 2003; 111(2): 339-345.
3. Hoogerwerf A, Schalij-Delfos NE, van Schooneveld MJ, Termote JUM. Incidence of retinopathy of prematurity over the last decade in the Central Netherlands. Neonatology. 2010; 98(2): 137-142.
4. Slidsborg C, Olesen HB, Jensen P.K., Jensen H., Nissen KR, Greisen G, Rasmussen S, Fledelius H.C., la Cour M. Treatment for retinopathy of prematurity in Denmark in a ten-year period (1996-2005): is the incidence increasing? Pediatrics. 2008; 121(1): 97-105.
5. Phan MH, Nguyen PN, Reynolds JD. Incidence and severity of retinopathy of prematurity in Vietnam, a developing middle-income country. J Pediatr Ophthalmol Strabismus. 2003; 40(4): 208-212.
6. Mutlu FM, Altinsoy HI, Mumcuoglu T, Kerimoglu H., Kilic S, Kul M, Sarici S.U., Alpay F. Screening for retinopathy of prematurity in a tertiary care newborn unit in Turkey: frequency, outcomes, and risk factor analysis. J Pediatr Ophthalmol Strabismus. 2008; 45(5): 291-298.
7. Mutlu FM, Sarici SU. Retinopathy of prematurity: incidence and risk factors. Exprt Rev Ophthalmol. 2007; 2(2): 267-274.
8. Saldir M, Sarici SU, Mutlu F.M., Mocan C., Altinsoy HI, Ozcan O. An analysis of neonatal risk factors associated with the development of ophthalmologic problems at infancy and early childhood: a study of premature infants born at or before 32 weeks of gestation. J Pediatr Ophthalmol Strabismus. 2010; 47(6): 331-337.
9. Gilbert C, Foster A. Childhood blindness in the context of VISION 2020 - the right to sight. Bull World Health Organ. 2001; 79(3): 227-232.
10. Fruttiger M. Development of the retinal vasculature. Angiogenesis. 2007; 10(2): 77-88.
11. Anand-Apte B., Hollyfield JG. Developmental anatomy of the retinal and choroidal vasculature. Encyclopedia of the Eye. 2010; 48: 9-15.
12. Saint-Geniez M., D'Amore PA. Development and pathology of the hyaloid, choroidal and retinal vasculature. Int J Dev Biol. 2004; 48(8-9): 1045-1058.
13. Watanabe T, Raff MC. Retinal astrocytes are immigrantsfrom the optic nerve. Nature. 1988; 332(6167): 834-837.
14. Stone J, Dreher Z. Relationship between astrocytes, ganglion cells and vasculature of the retina. J Comp Neurol. 1987; 255(1): 35-49.
15. Chu Y, Hughes S, Chan-Ling T. Differentiation and migration of astrocyte precursor cells and astrocytes in human fetal retina: relevance to optic nerve coloboma. FASEB J. 2001; 15(11): 2013-2015.
16. Hughes S, Yang H, Chan-Ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci. 2000; 41(5): 1217-1228.
17. McColm JR, Geisen P, Hartnett ME. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis. 2004; 10: 512-520.
18. Young TL, Anthony DC, Pierce E, Foley E., Smith LE. Histopathology and vascular endothelial growth factor in untreated and diode laser- treatedretinopathy of prematurity. J AAPOS. 1997; 1(2): 105-110.
19. Smith LE. Pathogenesis of retinopathy of prematurity. Semin Neonatol. 2003; 8(6): 469-473.
20. Chan-Ling T., McLeod DS, Hughes S, Baxter L., Chu Y, Hasegawa T, Lutty GA. Astrocyte-endothelial cell relationships during human retinal vascular development. Invest Ophthalmol Vis Sci. 2004; 45(6): 2020-2032.
21. Dorrell MI, Aguilar E, Friedlander M. Retinal vascular development is mediated by endothelial filopodia, a preexisting astrocytic template and specific R-cadherin adhesion. Invest Ophthalmol Vis Sci. 2002; 43(11): 3500-3510.
22. Weidemann A, Krohne TU, Aguilar E, Kurihara T., Takeda N, Dorrell MI, Simon M.C., Haase VH, Friedlander M, Johnson RS. Astrocyte hypoxic response is essential for pathological but not developmental angiogenesis of the retina. Glia. 2010; 58(10): 1177-1185.
23. Gariano RF, Iruela-Arispe ML, Hendrickson AE. Vascular development in primate retina: comparison of laminar plexus formation in monkey and human. Invest Ophthalmol Vis Sci. 1994; 35(9): 3442-3455.
24. Smith LE, Kopchick JJ, Chen W, Knapp J., Kinose F, Daley D, Foley E., Smith RG, Schaeffer JM. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science. 1997; 276(5319): 1706-1709.
25. Seghezzi G, Patel S, Ren C.J., Gualandris A., Pintucci G, Robbins ES, Shapiro R.L., Galloway AC, Rifkin DB, Mignatti P. Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: an autocrine mechanism contributing to angiogenesis. J Cell Biol. 1998; 141(7): 1659-1673.
26. Walshe TE, Saint-Geniez M, Maharaj A.S., Sekiyama E., Maldonado AE, D'Amore PA. TGF-beta is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature. PLoS One. 2009; 4(4): e5149.
27. Wilkinson-Berka J.L., Babic S, De Gooyer T, Stitt AW, Jaworski K, Ong L.G., Kelly DJ, Gilbert RE. Inhibition of platelet-derived growth factor promotes pericyte loss and angiogenesis in ischemic retinopathy. Am J Pathol. 2004; 164(4): 1263-1273.
28. Gille J, Khalik M, König V, Kaufmann R. Hepatocyte growth factor/scatter factor (HGF/SF) induces vascular permeability factor (VPF/VEGF) expression by cultured keratinocytes. J Invest Dermato. 1998; 111(6): 1160-1165.
29. Senger DR, Galli SJ, Dvorak A.M., Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983; 219(4587): 983-985.
30. Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol. 1996; 114(10): 1219-1228.
31. Löfqvist C., Andersson E, Sigurdsson J., Engström E, Hård AL, Niklasson A., Smith LE, Hellström A. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol. 2006; 124(12): 1711-1718.
32. Chen J, Stahl A, Hellstrom A., Smith LE. Current update on retinopathy of prematurity: screening and treatment. Curr Opin Pediatr. 2011; 23(2): 173-178.
33. Fielder AR, Posner EJ. London: Elsevier Churchill Livingstone; 2005. Neonatal ophthalmology. In: Rennie JM, editor. Robertons' Textbook of Neonatology; pp. 835-850.
34. Sonmez K, Drenser KA, Capone A, Jr, Trese MT. Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology. 2008; 115(6): 1065-1070.
35. Perez-Munuzuri A., Fernandez-Lorenzo JR, Couce-Pico ML, Blanco-Teijeiro MJ, Fraga-Bermúdez JM. Serum levels of IGF1 are a useful predictor of retinopathy of prematurity. Acta Paediatr. 2010; 99(4): 519-525.
36. Chen J, Smith LEH. Retinopathy of prematurity. Angiogenesis. 2007; 10(2): 133-140.
37. Hellström A., Engström E, Hård AL, Albertsson-Wikland K, Carlsson B., Niklasson A, Löfqvist C, Svensson E., Holm S, Ewald U, Holmström G, Smith LE. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics. 2003; 112(5): 1016-1020.
38. Sato T, Kusaka S, Shimojo H., Fujikado T. Simultaneous analyses of vitreous levels of 27 cytokines in eyes with retinopathy of prematurity. Ophthalmology. 2009; 116(11): 2165-2169.
39. Bizzarro MJ, Hussain N, Jonsson B., Feng R, Ment LR, Gruen J.R., Zhang H., Bhandari V. Genetic susceptibility to retinopathy of prematurity. Pediatrics. 2006; 118(5): 1858-1863.
40. Shastry BS. Genetic susceptibility to advanced retinopathy of prematurity (ROP) J Biomed Sci. 2010; 17(1): 69.
41. Hiraoka M, Takahashi H, Orimo H., Hiraoka M, Ogata T, Azuma N. Genetic screening of Wnt signaling factors in advanced retinopathy of prematurity. Mol Vis. 2010; 16: 2572-2577.
42. Vannay A, Dunai G, Bányász I, Szabó M, Vámos R, Treszl A, Hajdú J, Tulassay T, Vásárhelyi B. Association of genetic polymorphisms of vascular endothelial growth factor and risk for proliferative retinopathy of prematurity. Pediatr Res. 2005; 57(3): 396-398.
43. Cooke WI, Drury JA, Mountford R, Clark D. Genetic polymorphisms and retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2004; 45(6): 1712-1715.
44. Connolly BP, Ng EY, McNamara J.A., Regillo CD, Vander JF, Tasman W. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 2. Refractive outcome. Ophthalmology. 2002; 109(5): 936-941.
45. Ng EY, Connolly BP, McNamara J.A., Regillo CD, Vander JF, Tasman W. A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome. Ophthalmology. 2002; 109(5): 928-934.
46. Early Treatment for Retinopathy of Prematurity Cooperative Group Revised indications for treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Randomized Trial. Arch Ophthalmol. 2003; 121(12): 1684-1696.
47. Naug H, Browning J, Gole G.A., Gobe G. Vitreal macrophages express VEGF165 in oxygen-induced retinopathy. Clin Experiment Ophthalmol. 2000; 28(1): 48-52.
48. Travassos A, Teixeira S, Ferreira P., Regadas I, Travassos AS, Esperancinha F.E., Prieto I., Pires G, van Velze R, Valido A, Machado Mdo C. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Laser Imag. 2007; 38(3): 233-237.
49. Chung EJ, Kim JH, Ahn H.S., Koh HJ. Combination of laser photocoagulation and intravitrealbevacizumab (Avastin) for aggressive zone I retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol. 2007; 245(11): 1727-1730.
50. Mintz-Hittner H.A., Kuffel RR., Jr Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II. Retina. 2008; 28(6): 831-838.
51. Altinsoy HI, Mutlu FM, Gungor R, Sarici SU. Combination of laser photocoagulation and intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging. 2010 Mar 9: 1-5. doi: 10.3928/15428877-20100215-03.
52. Lee JY, Chae JB, Yang S.J., Yoon YH, Kim JG. Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol. 2010; 248(9): 1257-1262.
53. Mintz-Hittner H.A., Kennedy KA, Chuang A.Z., BEAT-ROP Cooperative Group Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med. 2011; 364(7): 603-615.
54. Filippi L, Cavallaro G, Fiorini P., Daniotti M, Benedetti V, Cristofori G., Araimo G, Ramenghi L, La Torre A, Fortunato P, Pollazzi L., la Marca G, Malvagia S, Bagnoli P, Ristori C, Dal Monte M, Bilia AR, Isacchi B, Furlanetto S, Tinelli F, Cioni G, Donzelli G, Osnaghi S, Mosca F. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr. 2010; 10: 83.
55. Hard AL, Hellstrom A. On the use of antiangiogenetic medications for retinopathy of prematurity. Acta Paediatr. 2011; 100(8): 1063-1065.
56. Chowers I, Banin E, Hemo Y., Porat R, Falk H, Keshet E., Pe'er J, Panet A. Gene transfer by viral vectors into blood vessels in a rat model of retinopathy of prematurity. Br J Ophthalmol. 2001; 85(8): 991-995.
57. Rajappa M, Saxena P, Kaur J. Ocular angiogenesis: mechanisms and recent advances in therapy. Adv Clin Chem. 2010; 50: 103-121.
58. Connor KM, SanGiovanni JP, Lofqvist C, Aderman C.M., Chen J., Higuchi A, Hong S, Pravda E.A., Majchrzak S., Carper D, Hellstrom A, Kang J.X., Chew EY, Salem N, Jr, Serhan CN, Smith LE. Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nat Med. 2007; 13(7): 868-873.
59. Stahl A, Sapieha P, Connor K.M., Sangiovanni JP, Chen J, Aderman CM, Willett K.L., Krah NM, Dennison RJ, Seaward MR, Guerin K.I., Hua J., Smith LE. Short communication: PPAR gamma mediates a direct antiangiogenic effect of omega 3-PUFAs in proliferative retinopathy. Circ Res. 2010; 107(4): 495-500.
60. Löfqvist C., Niklasson A, Engström E, Friberg L.E., Camacho-Hübner C, Ley D, Borg J, Smith LE, Hellström A. A pharmacokinetic and dosing study of intravenous insulin-like growth factor-I and IGF-binding protein-3 complex to preterm infants. Pediatr Res. 2009; 65(5): 574-579.
61. Smith LE. Through the eyes of a child: understanding retinopathy through ROP. The Friedenwald Lecture. Invest Ophthalmol Vis Sci. 2008; 49(12): 5177-5182.
62. Mintz-Hittner HA. Avastin as monotherapy for retinopathy of prematurity. J AAPOS. 2010; 14(1): 2-3.
63. Kong L, Mintz-Hittner HA, Penland R.L., Kretzer FL, Chévez-Barrios P. Intravitreal bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study. Arch Ophthalmol. 2008; 126(8): 1161-1163.
64. Autrata R, Krejcírová I, Senková K, Holoušová M, Doležel Z, Borek I. Intravitreal pegaptanib combined with diode laser therapy for stage 3+ retinopathy of prematurity in zone I and posterior zone II. Eur J Ophthalmol. 2012; 22(5): 687-694.
65. Mota Á, Carneiro Â, Breda J, Rosas V, Magalhães A, Silva R, Falcão-Reis F. Combination of intravitreal ranibizumab and laser photocoagulation for aggressive posterior retinopathy of prematurity. Case Rep Ophthalmol. 2012; 3: 136-141.
66. Stewart MW. The Expanding role of vascular endothelial growth factor inhibitors in Ophthalmology. Mayo Clin Proc. 2012; 87: 77-88.
67. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012; 6: 1175-1186.
68. Taugourdeau-Raymond S., Rouby F, Default A., Jean-Pastor MJ. Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database. Eur J Clin Pharmacol. 2012; 68(7): 1103-1107.
69. Wu WC, Yeh PT, Chen S.N., Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology. 2011; 118(1): 176-183.
70. Qian J, Lu Q, Tao Y., Jiang YR. Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy. Retina. 2011; 31(1): 161-168.
71. Matsuyama K, Ogata N, Matsuoka M., Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010; 94(9): 1215-1218.
72. Bakri SJ, Snyder MR, Reid J.M., Pulido JS, Singh RJ. Pharmocokinetics of intravitreal bevacizumab (Avastin) Ophthalmology. 2007; 114(5): 855-859.
73. Krohne T, Eter N, Holz F., Meyer C. Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am J Ophthalmol. 2008; 146(4): 508-512.
74. Heiduschka P, Fietz H, Hofmeister S., Schultheiss S, Mack AF, Peters S, Ziemssen F., Niggemann B, Julien S, Bartz-Schmidt KU, Schraermeyer U., Tübingen Bevacizumab Study Group Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci. 2007; 48(6): 2814-2823.
75. Sato T, Wada K, Arahori H., Kuno N, Imoto K, Iwahashi-Shima C, Kusaka S. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am J Ophthalmol. 2012; 153(2): 327-333.
76. Trese MT. Anti-angiogenesis therapy for early and late retinopathy of prematurity. 2007. p. 97. Angiogenesis Meeting 23-24 February 2007; Bascom Palmer Florida, USA.
77. Mandriota SJ, Menoud PA, Pepper MS. Transforming growth factor-β1 downregulates vascular endothelial growth factor receptor 2/flk-1 expression in vascular endothelial cells. J Biol Chem. 1996; 271(9): 11500-11505.
78. Krummel TM, Michna BA, Thomas B.L., Sporn MB, Nelson JM, Salzberg AM, Cohen I.K., Diegelmann RF. Transforming growth factor beta (TGF-beta) induces fibrosis in a fetal wound model. J Pediatr Surg. 1988; 23(7): 647-652.
79. Sancho MA, Juliá V, Albert A, Díaz F, Morales L. Effect of environment on fetal skin wound healing. J Pediatr Surg. 1997; 32(5): 663-666.
80. Mutlu FM, Altinsoy HI, Sobaci G, Gungor R., Sarici SU. Intravitreal bevacizumab in aggressive posterior ROP. 2010. p. 203. 16-19 October 2010 AAO and MEACO Meeting, Chicaco, USA Final Program.
81. Mintz-Hittner H.A., Best LM. Antivascular endothelial growth factor for retinopathy of prematurity. Curr Opin Pediatr. 2009; 21(2): 182-187.
82. Hurwitz HI, Fehrenbacher L, Hainsworth J.D., Heim W., Berlin J, Holmgren E, Hurwitz H.I., Fehrenbacher L., Hainsworth JD, Heim W, Berlin J, Holmgren E., Hambleton J, Novotny WF, Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol. 2005; 23(15): 3502-3508.
83. Hård A.L., Hellström A. On safety, pharmacokinetics and dosage of bevacizumab in ROP treatment: a review. Acta Paediatr. 2011; 100(12): 1523-1527.
84. Simon M, Grone HJ, Johren O, Kullmer J., Plate KH, Risau W, Fuchs E. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol. 1995; 268(2 Pt 2): F240-250.
85. Thebaud B. Angiogenesis in lung development, injury and repair: implications for chronic Lung disease of prematurity. Neonatology. 2007; 91(4): 291-297.
86. Sentilhes L, Michel C, Lecourtois M., Catteau J, Bourgeois P, Laudenbach V., Marret S, Laquerrière A. Vascular endothelial growth factor and its high-affinity receptor (VEGFR-2) are highly expressed in the human forebrain and cerebellum during development. J Neuropathol Exp Neurol. 2010; 69(2): 111-128.
87. Moshfeghi DM, Berrocal AM. Retinopathy of prematurity in the time of bevacizumab: incorporating the BEAT-ROP results into clinical practice. Ophthalmology. 2011; 118(7): 1227-1228.
88. Blair M, Shapiro MJ. Bevacizumab for ROP. Ophthalmology. 2012; 119(2): 431-432.
89. American Academy of Pediatrics Section on Ophthalmology; American Academy of Ophthalmology; American Association for Pediatric Ophthalmology and Strabismus; American Association of Certified Orthoptists Screening examination of premature infants for retinopathy of prematurity. Pediatrics. 2013; 131(1): 189-195.
90. Ristori C, Filippi L, Dal Monte M, Martini D, Cammalleri M., Fortunato P, la Marca G, Fiorini P, Bagnoli P. Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade. Invest Ophthalmol Vis Sci. 2011; 52(1): 155-170.
91. Chen J, Joyal JS, Hatton C.J., Juan AM, Pei DT, Hurst CG, Xu D, Stahl A., Hellstrom A, Smith LE. Propranolol inhibition of β-adrenergic receptor does not suppress pathologic neovascularization in oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 2012; 53(6): 2968-2977.
92. de Graaf M., Breur JM, Raphaël MF, Vos M., Breugem CC, Pasmans SG. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants. J Am Acad Dermatol. 2011; 65(2): 320-327.
93. Fonseca VA. Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin. 2010; 26(3): 615-629.
94. Hunt S. Increased dietary intake of omega-3-PUFA reduces pathological retinal angiogenesis. Ophthalmologe. 2007; 104(8): 727-729.
95. Innis SM. Essential fatty acid transfer and fetal development. Placenta. 2005; 26(Suppl A): S70-75.
96. Chen J, Connor KM, Aderman C.M., Willett KL, Aspegren OP, Smith LE. Suppression of retinal neovascularization by erythropoietin siRNA in a mouse model of proliferative retinopathy. Invest Ophthalmol Vis Sci. 2009; 50(3): 1329-1335.
97. Chen J, Connor KM, Aderman C.M., Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008; 118(2): 526-533.
98. Sato T, Kusaka S, Shimojo H., Fujikado T. Vitreous levels of erythropoietin and vascular endothelial growth factor in eyes with retinopathy of prematurity. Ophthalmology. 2009; 116(9): 1599-1603.
99. Suk KK, Dunbar JA, Liu A, Daher N.S., Leng CK, Leng JK, Lim P, Weller S., Fayard E. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS. 2008; 12(3): 233-238.
100. Neimeyer MS, Fayard E, Liu T., Dunbar J. Recombinant human erythropoietin (rhEpo) treatment and incidence of retinopathy of prematurity (ROP) Invest Ophthalmol Vis Sci. 2004; 45: E-Abstract 4025.
101. Shah N, Jadav P, Jean-Baptiste D, Weedon J., Cohen LM, Kim MR. The effect of recombinant human erythropoietin on the development of retinopathy of prematurity. Am J Perinatol. 2010; 27(1): 67-71.
102. Smith LE, Shen W, Perruzzi C., Soker S, Kinose F, Xu X., Robinson G, Driver S, Bischoff J., Zhang B, Schaeffer JM, Senger DR. Regulation of vascular endothelial growth factor dependent retinal neo-vascularization by insulin-like growth factor-1 receptor. Nat Med. 1999; 5(12): 1390-1395.
103. Capoluongo E, Vento G, Ameglio F., Lulli P, Matassa PG, Carrozza C, Santini S.A., Antenucci M., Castagnola M, Giardina B, Romagnoli C., Zuppi C. Increased levels of IGF-1 and beta2-microglobulin in epithelial lining fluid of preterm newborns developing chronic lung disease, effects of rhG-CSF. Int J Immunopathol Pharmacol. 2006; 19(1): 57-66.
104. Bhola R, Purkiss T, Hunter S., Stewart D, Rychwalski PJ. Effect of granulocyte colony-stimulating factor on the incidence of threshold retinopathy of prematurity. JAAPOS. 2009; 13(5): 450-453.
105. Niranjan HS, Benakappa N, Reddy K.B., Nanda S., Kamath MV. Retinopathy of prematurity-Promising newer modalities of treatment. Indian Pediatr. 2012; 49(2): 139-143.
106. Takahashi T, Kalka C, Masuda H., Chen D, Silver M, Kearney M., Magner M, Isner JM, Asahara T. Ischemia and cytokine-induced mobilization of bone marrow derived endothelial progenitor cells for neovascularization. Nat Med. 1999; 5(4): 434-438.
107. Saugstad OD. Oxidative stress in the newborn: a 30 year perspective. Biol Neonate. 2005; 88(3): 228-236.
108. Raju TN, Langenberg P, Bhutani V., Quinn GE. Vitamin E prophylaxis to reduce retinopathy of prematurity: a reappraisal of published trials. J Pediatr. 1997; 131(6): 844-850.
109. Law MR, Wijewardene K, Wald NJ. Is routine vitamin E administration justified in very low-birthweight infants? Dev Med Child Neurol. 1990; 32(5): 442-450.
110. Johnson L, Quinn GE, Abbasi S, Otis C., Goldstein D, Sacks L, Porat R., Fong E, Delivoria-Papadopoulos M, Peckham G, Schaffer D.B., Bowen FW., Jr Effect of sustained pharmacologic vitamin E levels on incidence and severity of retinopathy of prematurity: a controlled clinical trial. J Pediatr. 1989; 114(5): 827-838.